Biotech China 2014

View Profile


Speaking/Presenting-Abstract/Poster at Mtg

Topic Authors / presenters Event name Event date
1. Melanoma and skin cancers 2009 Oncology Highlights January, 2000
2. Skin Cancers. The Group Room Radio show, Van Nuys, CA. January, 2000
3. Anti-CTLA4 Antibodies 7th World Congress on Melanoma. January, 2000
4. Use of Dendritic Cells Transduced with the MART-1 Gene. UCLA Jonsson Cancer Center Conference January, 2000
5. Dendritic Cells: Immunological Effects in Mice. Third Annual UCLA Gene Medicine Symposium January, 2000
6. Cell Immunotherapy in Melanoma. UCLA Jonsson Cancer Center Conference January, 2000
7. Immunotherapy for Malignant Melanoma. University of Barcelona January, 2000
8. Immunotherapy for Hepatocellular Carcinoma. Autonomous University of Barcelona January, 2000
9. Immunotherapy for Malignant Melanoma with Dendritic Cells. Cancer Symposium Pfizer Global Research and Development, January, 2000
10. Immunotherapy for Melanoma 11th International Conference of Gene Therapy of Cancer January, 2000
11. Antitumor Protection in the Absence of CD8 Cells UCLA Jonsson Cancer Center Research Conference. January, 2000
12. Clinical Trials at the UCLA Melanoma Program. UCLA Oncology Network Retreat. January, 2000
13. Role of NK, CD4 and CD8 Cells in Response to Dendritic Cell Immunization. Human Gene Medicine lecture January, 2000
14. Cancer Immunotherapy and Tumor Vaccines. Cousins Center for Psychoneuroimmunology January, 2000
15. Immunotherapy for Melanoma. Gene Therapeutics Research Institute, Cedars Sinai Medical Center January, 2000
16. Protection from Tumor by NK Cells and CD4 T Cells in CD8 Null Mice by Dendritic Cell-Based Vaccination University of Connecticut January, 2000
17. Treatment of Malignant Melanoma. CTLA4 Symposium. Pfizer Global Research and Development January, 2000
18. Treatment of Malignant Melanoma. CTLA4 Symposium. Pfizer Global Research and Development, January, 2000
19. CTLA4-Based Immunotherapy for Melanoma. University of Barcelona January, 2000
20. Gene Therapy in Surgical Oncology 24th Panhellenic Congress of Surger January, 2000
21. How can we image clinical immunotherapy for melanoma? IMED-ICMIC meeting January, 2000
22. Translational Research in Melanoma Jonsson Comprehensive Cancer Center Board of Directors Meeting. UCLA. January, 2000
23. Symposium Chair and Presenter: Breaking Barriers in Tumor Immunology. 6th World Congress on Melanoma January, 2000
24. Update on the Treatment of Metastatic Melanoma University of Wisconsin CME Accredited Presentation January, 2000
25. Dendritic Cell Vaccines and anti-CTLA4 Antibodies to Treat Patients with Melanoma. 31st Annual La Jolla Immunology Conference January, 2000
26. Anti-CTLA4 antibodies alone and in combination for therapy of melanoma. Perspectives in Melanoma IV. January, 2000
27. How can we define an immune response using immunological assays? National Cancer Institute Immunotherapy Workshop, John Wayne Cancer Institute January, 2000
28. Good Manufacturing Practices Shared Resources External Advisory Board of the Jonsson Comprehensive Cancer Center January, 2000
29. Clinical trials with the anti-CTLA4 antibody ticilimumab (CP-675,206) in patients with melanoma. 2nd Annual Canadian Melanoma Conference January, 2000
30. MicroImmuno chips. Caltech-UCLA-ISB Nanosystems biology cancer center (NSBCC) retreat January, 2000
31. Translational oncology spotlight: Malignant Melanoma 2nd Int. Symposium on Translational Oncology, Barcelona, January, 2000
32. CTLA4 blocking monoclonal antibodies in the treatment of malignant melanoma. IV Interdisciplinary Oncology Symposium: Melanoma January, 2000
33. CTLA-4 Blocking Monoclonal Antibodies in the Treatment of Metastatic Melanoma. John Wayne Cancer Institute January, 2000
34. Targeting CTLA4 In 6th International Congress on Monoclonal Antibodies in Cancer January, 2000
35. Targeting CTLA4/B7/B7.1. In 5th International Congress on Targeted Therapies in Oncology January, 2000
36. Advanced Melanoma. A review of standards of care and new therapies in development. Web-based seminar, EmergingMed. January, 2000
37. Progress and future directions in the treatment of metastatic melanoma. In the Translational Oncology Research International annual meeting January, 2000
38. Monoclonal Antibodies for T Cell Activation. In 'Overcoming Barriers to Immune Therapy in Melanoma' symposium University of California San Diego January, 2000
39. Mechanisms of antitumor response using CTLA4 blocking antibodies. International Symposium: Immunology and Immunotherapy of Cancer. Pamplona January, 2000
40. CTLA4 blockade and in vivo imaging of anti-tumor T cells. At the 3rd Immunotherapy Workshop on Antibodies in Melanoma. John Wayne Cancer Institute January, 2000
41. Cancer Immunotherapy NanoSystems Biology Cancer Center Annual Retreat January, 2000
42. Clinical Data with CP-675,206. In: Immunotherapy for Melanoma. New Yo January, 2000
43. PET Imaging of Adoptive Transfer Immunotherapy. In the Keystone Symposia The Potent New Anti-Tumor Immunotherapies January, 2000
44. Immune Therapy for Melanoma: Emerging Therapies. In Reality Hematology-Oncology January, 2000
45. Breaking Immune Tolerance: a Step Forward in Melanoma Treatment. In UCSF 2nd International Symposium on Cancer Metastasis and the Lymphovascular System: Basis for Rational Therapy. January, 2000
46. Immunotherapy and Immune Monitoring in Malignant Melanoma. MannKind Corporation January, 2000
47. Anti-CTLA4. New Frontiers in Cancer Immunotherapy. Foundation Merieux, Annency, France. January, 2000
48. Malignant Melanoma 43rd ASCO meeting. Miami January, 2000
49. Autoimmunity in Melanoma Treatment First World Meeting of Melanoma Centers, Barcelona, Spain. January, 2000
50. CTLA4 Antibodies First World Meeting of Melanoma Centers January, 2000
51. Combination of Dendritic Cell Vaccines and Anti-CTLA4 Antibodies. National Cancer Institute Workshop, University of Texas at El Paso January, 2000
52. Prognostic Markers for Immunotherapy Trials. 9th Annual Colloquium on Cancer Vaccines and Immunotherapy and 2007 Annual Meeting of the Cancer Vaccine Consortium. January, 2000
53. Overcoming Immunological Tolerance to Melanoma: Targeting CTLA4 with Tremelimumab. Perspectives in Melanoma XI. January, 2000
54. The immune system as a target for therapy: Improving immune responses and breaking tolerance First Global Workshop on Malignant Melanoma January, 2000
55. Do Immune-Related Adverse Events Correlate With Clinical Outcome of Ant–CTLA-4 Agents? 5th International Symposium on Melanoma and Other Cutaneous Malignancies. January, 2000
56. Immunotherapy for Melanoma 2008 Hollings Cancer Center Spring Symposium. Medical University of South Carolina. January, 2000
57. New Developments in the Treatment of Malignant Melanoma of the Skin Annual Meeting of the American Association of Medical Audit Specialists (AAMAS). January, 2000
58. Melanoma and Skin Cancers 2008 Oncology Highlights. Dallas, TX. January, 2000
59. Review of tremelimumab development program and data. iSBTc Hot Topic Sunday Symposium. January, 2000
60. Immunotherapy: Where Are We in 2008 & 2009? Second Global Workshop on Malignant Melanoma. January, 2000
61. Where are we now and where are we going with tremelimumab? Second Worldwide Meeting of Melanoma Centers January, 2000
62. Stem Cell-based Engineered Immunity. Immunology Workshop, California Institute for Regenerative Medicine (CIRM), January, 2000
63. Treatment of Metastatic Melanoma and the Role of Targeted Therapies. 33rd Hawaii Dermatology Seminar of the Skin Disease Education Foundation (SDEF) January, 2000
64. Anti-CTLA4 Antibody Therapy: Is This Another IL-2? and Targeting the Tumor Cell or the Immune Cell: Are We Barking Up the Wrong Tree? 6th International Symposium on Melanoma and Other Cutaneous Malignancies. January, 2000
65. Invasive and non-invasive monitoring for cancer immune therapy. US-Japan workshop on immunological molecular markers in oncology. January, 2000
66. Management of CTLA-4 antibody related toxicity. 3rd World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers. January, 2000
67. [Estudio en fase II de ifosfamida a altas dosis sin soporte hematologico en canceres de mama (CM), de vejiga (CV) y sarcomas (S) refractarios a quimioterapia convencional]. 4as Jornadas Invernales de Actualización en Oncología, Formigal, Spain. January, 2000
68. Estudio en fase II de metotrexato, carboplatino y vinblastina (M-CAVI) en el tratamiento neoadyuvante del cáncer de vejiga V Congreso de la Sociedad Española de Oncología Médica, Granada, Spain. January, 2000
69. Treatment of established tumors with gene-modified murine dendritic cells. (Abstract 128) Sixth International Conference on Cancer Gene Therapy, San Diego, CA January, 2000
70. Standardization of MHC Tetramer and ELISPOT Assays to Quantitate Antigen-Specific T Cell Expansion after CTLA4 Blockade International Society of Biological Therapy for Cancer (iSBTc). San Francisco, CA. January, 2000
71. Changes in Intratumoral Immune Cell Infiltrates, Foxp3 and Indoleamine 2, 3-dioxygenase (IDO) Expression with the CTLA4 Blocking mAb CP-675,206 International Society for Biological Therapy of Cancer (iSBTc), Los Angeles, CA January, 2000
72. Adoptive Immunotherapy with Melanoma Antigen-specific T cells for CNS Tumors and In Vivo Imaging of T cell Trafficking. The Potent New Anti-Tumor Immunotherapies. Keystone Symposia, Banff, Canada. January, 2000
73. Results of a phase II clinical trial of 2 doses and schedules of CP-675,206, an anti-CTLA4 monoclonal antibody, in patients (pts) with advanced melanoma. Annual Meeting of the American Society of Clinical Oncology (ASCO) January, 2000
74. Combination of Dendritic Cell (DC) Vaccination with CTLA4 Blockade in Patients (pts) with Metastatic Melanoma: A Phase 1 Clinical Trial Annual Meeting of the American Association for Cancer Research (AACR), San Diego, CA. January, 2000
75. Phase III, Open-Label, Randomized, Comparative Study of Tremelimumab (CP-675,206) and Chemotherapy (Temozolomide or Dacarbazine) in Patients with Advanced Melanoma. Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, IL January, 2000
76. Melanoma Oral Session Annual Meeting of the American Society of Clinical Oncology (ASCO), Orlando, FL. January, 2000
77. Treatment of Malignant Melanoma. Marion Cancer Center, Santa Maria, CA. January, 2000
78. UCLA Translational Research for Malignant Melanoma. Division of Hematology/Oncology Grand Rounds. UCLA, Los Angeles January, 2000
79. Immunotherapy for Melanoma Department of Medicine Grand Rounds, Veteran’s Administration Hospital, Los Angeles January, 2000
80. Immunotherapy for Melanoma. Division of Dermatology Grand Rounds, UCLA, Los Angeles, CA. January, 2000
81. AFP-Based Immunotherapy for Hepatocellular Carcinoma. Division of Hematology/Oncology Grand Rounds. UCLA, Los Angeles January, 2000
82. Immunotherapy for Melanoma. Division of Gynecological Oncology Grand Rounds, Cedars Sinai Medical Center, Los Angeles January, 2000
83. Dendritic Cell Vaccines and CTLA4 Blockade in Patients with Malignant Melanoma. UCLA Pathology Seminar Series, Los Angeles January, 2000
84. developments in the treatment of metastatic melanoma. Nevada Cancer Institute, Las Vegas January, 2000
85. New Treatment Approaches for Advanced Melanoma UCLA Division of Dermatology Grand Rounds, Los Angeles, CA. January, 2000
86. Systemic Therapy for Metastatic Melanoma Department of Dermatology Grand Rounds. Harbor UCLA Medical Center, Los Angeles January, 2000
87. New immunotherapy strategies for 2007. Colorado University Grand Rounds January, 2000
88. Immunotherapy for Melanoma. Medical Oncology, Hematology and Pathology lecture. City of Hope National Medical Center January, 2000
89. Metastatic Malignant Melanoma. Saddleback Memorial Hospital Grand Rounds and CME program, Laguna Hills, CA January, 2000
90. TCR Engineering and Immunosensitization. Department of Medicine Grand Rounds. University of Pittsburgh. Pittsburgh, PA. January, 2000
91. Advances in the Immunotherapy for Metastatic Melanoma. Division of Hematology-Oncology Grand Rounds University of Alabama at Birmingham, Birmingham, AL. January, 2000
92. Immunotherapy for Melanoma. Division of Research Immunology/Bone Marrow Transplantation. Children’s Hospital of Los Angeles, Los Angeles, CA. January, 2000
93. Immunotherapy for Melanoma. Department of Medicine Grand Rounds. Harbor-UCLA Medical Center, Los Angeles, CA. January, 2000
94. Immunotherapy for Melanoma. Department of Medicine Grand Rounds. Santa Monica Hospital-UCLA, Santa Monica January, 2000
95. Immunotherapy for Melanoma. Division of Hematology-Oncology, UCLA, Los Angeles, CA. January, 2000
96. Young Investigator and Career Development Awards for Hematology-Oncology Fellows. Division of Hematology-Oncology, UCLA, Los Angeles, CA. January, 2000
97. Targeted therapy for melanoma Department of Medicine, Santa Monica UCLA, Santa Monica, CA. January, 2000
98. Immunotherapy for Melanoma. Department of Medicine Grand Rounds, UCLA, Los Angeles, CA. January, 2000
99. New Treatment Strategies for Metastatic Melanoma Department of Dermatology Grand Rounds, University of California San Diego, San Diego, CA. January, 2000
100. New Immunotherapies for Metastatic Melanoma Gene Therapy Center Grand Rounds. University of Alabama at Birmingham, January, 2000
101. TCR engineering adoptive transfer therapy Division of Hematology-Oncology. UCLA. January, 2000
102. Melanoma treatment with BRAF inhibitors Department of Radiation Oncology, UCLA. January, 2000
103. BRAF inhibitors in melanoma Department of Internal Medicine, Santa Monica-UCLA Hospital. January, 2000
104. TCR engineering adoptive cell transfer therapy for melanoma. Jonsson Comprehensive Cancer Center, UCLA. January, 2000
105. TCR engineering for the treatment of metastatic melanoma. University of Connecticut, Farmington, CN. January, 2000
106. Clinical Trials of Immunotherapy for Malignant Melanoma at UCLA. Stop Cancer Founder's Forum. UCLA, Los Angeles, CA. January, 2000
107. Medical Management of Melanoma The Melanoma Research Foundation. Los Angeles, CA. January, 2000
108. Cancer Vaccines Insights into Cancer Series, Ted Mann Family Resource Center, Los Angeles, CA. January, 2000
109. Cancer Vaccines for Malignant Melanoma Partners In Research evening, Israel Cancer Research Fund, Beverly Hills, CA. January, 2000
110. What are phase I trials and what are some leads that are promising? Melanoma Symposium for Physicians and Community Members. UCI Chao Family Comprehensive Cancer Center. January, 2000
111. Seminar host: Advanced Melanoma A review for patients of evidence supporting the standards of care and new therapies in development. Web-based seminar, EmergingMed. January, 2000
112. Cancer Vaccines. Insights Into Cancer Series Ted Mann Family Resource Center, Los Angeles, CA. January, 2000
113. Melanoma of the Skin and Eye: Treatment Strategies for Local and Widespread Disease. Insights Into Cancer Series, Simms/Mann UCLA Center for Integrative Oncology, Los Angeles, CA. January, 2000
114. New Developments in the Treatment of Metastatic Melanoma: BRAF Targeted Therapy and Adoptive Transfer Immunotherapy Vall Hebron Research Institute, Autonomous University of Barcelona, Barcelona, Spain. January, 2000



Site wide Speaking/Presenting-Abstract/Poster at Mtg

Presentation Event Month, Year
Novel Therapeutic Concepts with Kinases, Immuno-, and Radiotherapy Chairperson: Charles L. Sawyers, Memorial Sloan-Kettering Cancer Center, New York, NY AACR Annual Meetings April, 2013
Elucidating immunomodulation | New murine melanoma models 2012 Annual Paris Melanoma Conference April, 2012
Importance of AKT/MTOR pathway involvement 2012 Annual Paris Melanoma Conference April, 2012
SESSION VII | Molecular Pathways and Applications in Basal Cell Carcinoma and Merkel Tumors 2012 Annual Paris Melanoma Conference April, 2012
Understanding clinical resistance to further personalized medicine in melanoma 3rd Quebec Conference on Therapeutic Resistance in Cancer March, 2012
Combining Chemotherapy With Immunotherapy: Does It Make Sense? Seventh International Symposium on Melanoma and Other Cutaneous Malignancies March, 2010
Session 9: Enhancing Immune System Surveillance and Response Seventh International Symposium on Melanoma and Other Cutaneous Malignancies March, 2010

4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.